Bromoacetamido-PEG4-acid
Based on 1 Customer Validation
Bromoacetamido-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Bromoacetamido-PEG4-acid is also a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
For research use only. We do not sell to patients.
- Purity: 96.82%
- CAS No.: 1807518-67-7
- Formula: C13H24BrNO7
- Molecular Weight:386.24
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All PROTAC Linkers Isoforms
More
Biological Activity
|
PEGs |
Cleavable Linker |
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1807518-67-7
-
Appearance Liquid (Density: 1.368±0.06 g/cm3)
-
Molecular Weight 386.24
-
Formula C13H24BrNO7
-
Color Colorless to light yellow
-
SMILES
O=C(O)CCOCCOCCOCCOCCNC(CBr)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (614 KB)
- English - EN (614 KB)
- Français - FR (614 KB)
- Deutsch - DE (614 KB)
- Norwegian - NO (614 KB)
- Español - ES (614 KB)
- Swedish - SV (614 KB)
- Italian - IT (614 KB)
- Korean - KR (614 KB)
- Portuguese - PT (614 KB)
-
Handling Instructions (2659 KB)
References
[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562. [Content Brief]
[2]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bromoacetamido-PEG4-acid Related Classifications
HY-141382 Related Classifications
Powered by Bioz